- Poster presentation
- Open Access
The evaluation of the disease advancement in patients with mucopolysaccharidosis
Pediatric Rheumatology volume 12, Article number: P153 (2014)
One of the most important manifestations of mucopolysaccharidosis (MPS) type I, II and VI is a progressive disease of the osteoarticular system. The evaluation of the disease advancement is difficult due to the complexity of symptoms. The characteristic features are progressive limitation of joint mobility and joint pain. These symptoms affect the quality of patient life. A uniform scale has not been developed for these patients.
The aim of this study was to use the experience in the evaluation of disorders in rheumatic diseases (Juvenile Idiopathic Arthritis, JIA) in patients with MPS.
6 patients with MPS VI were evaluated: 2 with advanced disease, 2 with moderate and 2 with slow progressing disease. The following parameters were selected for assessment: Physician global assessment of disease activity (PGA), Patient/parent global assessment of well-being (PGE), Functional ability (CHAQ), Number of joints with limited movement (LJC) and VAS pain – visual analogue scale for pain.
The evaluation results are shown in Table 1.
The parameters used in JIA may be applied for assessment of the MPS severity. With their implementation, the progression of the disease and the effect of the treatment can be assessed and compared.
Disclosure of interest
About this article
Cite this article
Opoka-Winiarska, V. The evaluation of the disease advancement in patients with mucopolysaccharidosis. Pediatr Rheumatol 12, P153 (2014). https://doi.org/10.1186/1546-0096-12-S1-P153
- Visual Analogue Scale
- Juvenile Idiopathic Arthritis
- Rheumatic Disease
- Global Assessment